Lixte Biotechnology Holdings, Inc. (LIXT)
Stock Price:
$1.16 USD
0.00 (0.00%)
Updated Oct 23, 2020 9:30 AM EDT - Market closed
Key Info
| Market Cap |
12.96M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-2.16M |
| Shares Out |
11.17M |
| EPS (ttm) |
-0.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$1.16 |
| Previous Close |
$1.16 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
1.16 |
| Day's Range |
1.16 - 1.16 |
| Day's Volume |
0 |
| 52-Week Range |
0.6 - 1.2 |
More Stats
| Market Cap |
12.96M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.17M |
| Float |
3.12M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.03 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
-0.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
322.42 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-2.16M |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
n/a |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-49.54% |
| ROE |
-85.04% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Lixte Biotechnology Holdings, Inc. |
| Country |
United States |
| Employees |
1 |
| CEO |
John S. Kovach |
Stock Information
| Ticker Symbol |
LIXT |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: LIXT |
Description
Lixte Biotechnology Holdings operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primary focuses on developing various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gaucher's disease; and depression and post-traumatic stress syndrome. It develops protein phosphatase inhibitors that include LB-100 series of compounds; and histone deacetylase inhibitors, which comprises LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases, which are under various stages of pre-clinical and clinical developments. The company has a collaboration agreement with the Foundation for Angelman Syndrome Therapeutics to support the preclinical study of LB-100, a protein phosphatase 2A inhibitor for the treatment of angelman syndrome. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in East Setauket, New York.